Canadian royalty investor buys into first-of-its-kind Type 1 diabetes drug

[Amity Island]

DRI Healthcare Trust, a prolific acquirer of drug royalties, is paying $100 million for a piece of a first-of-its-kind Type 1 diabetes drug.


In an announcement Thursday, DRI said it bought royalties to the medicine, called Tzield and designed to delay the onset of Type 1 diabetes, from biotechnology company Macrogenics. The FDA approved Tzield last November for individuals over the age of 8 who are considered to be in Stage 2, or “at risk,” of the autoimmune disease.


Provention Bio, Tzield’s owner, is currently testing the drug in a Phase 3 study of newly diagnosed patients with Stage 3 disease.

Canadian royalty investor buys into first-of-its-kind Type 1 diabetes drug

DRI Healthcare, which owns royalties on top-selling drugs like Eylea and Stelara, is paying $100 million for a piece of the Provention Bio drug Tzield that the FDA approved last year.

www.biopharmadive.com

 

[everydayupsanddowns]

Hadn't heard stages of T1 being discussed before. They are pretty much what you might imagine.

This was suggested in 2015:

Stage 1 is defined as the presence of β-cell autoimmunity as evidenced by the presence of two or more islet autoantibodies with normoglycemia and is presymptomatic.
Stage 2 as the presence of β-cell autoimmunity with dysglycemia and is presymptomatic, and
Stage 3 as onset of symptomatic disease.

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association

Insights from prospective, longitudinal studies of individuals at risk for developing type 1 diabetes have demonstrated that the disease is a continuum that pro

diabetesjournals.org